OR WAIT null SECS
PRA announced it has completed its 20th first in human trial with biologics.
PRA announced it has completed its 20th first in human trial with biologics. The milestone is the culmination of 600 subjects enrolled in over eight years of first in human biologics trials, including directly into patient experience. Biologics represent an important class of agents with an increasing share in modern medicine, as a response to improved understanding of molecular and genetic bases of disease.
Read the full release here.